Clinical Trial

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-09-20; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2024-10-30
Trial Details
NCT Number NCT06609005
Lead Sponsor Shenzhen Ionova Life Sciences Co., Ltd.
Conditions Advanced Metastatic Castration Resistant Prostate Cancer
Enrollment 84 participants
Start Date 2025-01-23
Primary Completion 2028-01-17 (estimated)
Study Completion 2028-01-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-04